AGILENT TECHDRNAA

AGILENT TECHDRN

442.66BRLD
+9.66+2.23%
At close at Feb 8, 07:52 GMT
BRL
No trades
See on Supercharts

A1GI34 fundamentals

Key facts

Market capitalization‪220.63 B‬BRL
Founded1999
Employees (FY)‪17.9 K‬
CEOPadraig Mcdonnell
About

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪220.63 B‬‬
Price to earning ratio (P/E)
37,652.17x
Price to sales ratio (P/S)
7.32x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
37,652.17x
Price to sales ratio (P/S)
7.32x
Valuation ratios
‪0.00‬
‪1.70‬
‪3.40‬
‪5.10‬
‪6.80‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪9.00 K‬‬
‪‪18.00 K‬‬
‪‪27.00 K‬‬
‪‪36.00 K‬‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪15.0%‬
‪18.5%‬
‪22.0%‬
‪25.5%‬
‪29.0%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Life Sciences and Applied Markets
Diagnostics and Genomics
Agilent CrossLab
By country
Period: 2024
United States
Europe
China including Hong Kong
Asia Pacific
Americas

Dividends

Dividend yield, history and sustainability

Dividend summary
14,815.16%
Payout ratio (TTM)
Dividend yield TTM
0.41%
Next payment
0.478
Next ex-date
Mar 31, 2025
Dividend history
‪0.30%‬
‪0.37%‬
‪0.44%‬
‪0.51%‬
‪0.58%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.50‬
‪1.00‬
‪1.50‬
‪2.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬
‪‪18.00 B‬‬
‪‪24.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪12.00 B‬‬
‪‪24.00 B‬‬
‪‪36.00 B‬‬
‪‪48.00 B‬‬
Assets
Liabilities